Cargando…
Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis
Constitutive activation of the Janus kinase/signal transduction and activator of transcription (JAK-STAT) signaling pathway plays a central role in the pathogenesis of myelofibrosis (MF) and pulmonary hypertension (PH) is a known complication of MF. On the other hand, it has been proposed that the J...
Autores principales: | Miyawaki, Hiroshi, Kioka, Hidetaka, Sato, Kazuaki, Kurashige, Masako, Ozawa, Takayuki, Shibayama, Hirohiko, Hikoso, Shungo, Morii, Eiichi, Yamauchi-Takihara, Keiko, Sakata, Yasushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008043/ https://www.ncbi.nlm.nih.gov/pubmed/31534088 http://dx.doi.org/10.2169/internalmedicine.3528-19 |
Ejemplares similares
-
Polycythemia Vera Associated with Pulmonary Hypertension and Diffuse Large B-Cell Lymphoma: A Case Report
por: Kameda, Satoshi, et al.
Publicado: (2021) -
Successful treatment of severe combined post- and pre-capillary pulmonary hypertension in a patient with idiopathic restrictive cardiomyopathy
por: Ishihara, Satomi, et al.
Publicado: (2018) -
Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure
por: Taneike, Manabu, et al.
Publicado: (2021) -
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023) -
Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)